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Background: Intravenous immunoglobulin (IVIG) is effective as standard first line therapy
for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), but some patients
remain dependent on its long-term use. Recently, we have reported that autologous
non-myeloablative hematopoietic stem cell transplantation (HSCT) is an effective second
line therapy for CIDP.
Objectives: To compare the cost of chronic IVIG vs. autologous HSCT (a one-time
therapy), we collected data on patients with CIDP undergoing HSCT between 2017 and
2019. This was compared with published literature on the costs and efficacy defined
by the Inflammatory Neuropathy Cause And Treatment (INCAT) disability score, Medical
Research Council (MRC) sum score, hand grip strength, and SF-36 quality of life (QOL)
for CIDP.
Methods: Between 2017 and 2019, nineteen patients with chronic CIDP (mean disease
treatment duration prior to HSCT of 6 years) underwent autologous HSCTwith mean cost
of $108,577 per patient (range $56,327–277,119, standard deviation $53,092). After
HSCT, 80% of patients remain IVIG and immune treatment free for up to 5 years. In
comparison, published cost of IVIG treatment in the USA for an average CIDP patient
exceeds $136,000 per year. Despite remaining treatment free, HSCT demonstrated
greater improvement in efficacy compared to immunoglobulins.
Recommendations: Given the long-term treatment-free remission and better outcome
measurements, autologous HSCT is more cost effective than long-term IVIG treatment
in patients with chronic CIDP. However, costs will depend on patient selection, the
HSCT regimen, and regional variations. Further analysis of the health economics,
i.e., cost/outcome ratio, of HSCT as therapy for chronically IVIG dependent CIDP
is warranted.
Keywords: health economics, immunoglobulin, hematopoietic stem cell transplantation, CIDP, cost
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INTRODUCTION
CIDP is a demyelination disease of the peripheral nervous system
that may pursue a monophasic course of more than 2 months
before remitting, follow a relapsing-remitting course, or maintain
a chronic progressive course. In its classical presentation, CIDP is
characterized by bilateral symmetrical motor and sensory deficits
that occur in both the proximal and distal peripheral nervous
system and by diminished tendon reflexes (1, 2). “Atypical” CIDP
variants are: multifocal acquired demyelinating sensory and
motor (MADSAM) (also known as Lewis-Sumner Syndrome),
distal acquired demyelinating symmetric (DADS), and pure
motor or pure sensory polyneuropathy. CIDP is a rare disease,
affecting 1.6–10.3/100,000 adults and is one of the few peripheral
neuropathies that responds to immune based therapies.
First line therapies are corticosteroids, IVIG (3, 4),
subcutaneous immunoglobulin (SCIg) (5), and plasmapheresis
(PLEX) (6). However, some patients fail to respond to first-line
treatments (7) or respond but become dependent on their long-
term use (8). Depending on the literature, 25–60% of patients
can be weaned off their treatment (9, 10) while ∼15–30%
remain refractory to and/or dependent on treatments (11). IVIG
and SCIg are expensive, especially when required for chronic
long-term treatment, restrict quality of life, and may have
significant side effects including anaphylaxis, aseptic meningitis,
and maintenance of and complications from chronic intravenous
access. The financial burden of chronic IVIG or losing
employment and subsequent loss of employment insurance
benefits can prevent or be a significant hindrance to continuation
of expensive long-term treatment with IVIG (12–15).
We have previously demonstrated that non-myeloablative
autologous HSCT is effective in inducing a drug free clinical
remission in patients with CIDP who failed or are dependent on
either IVIG and or PLEX (16). FollowingHSCT up to 80% of such
patients became free of all immune based treatments including
IVIG over a follow-up interval of 5 years (16). Further, treated
patients had significant improvements in INCAT disability score,
MRC sum score, hand grip strength, SF-36 QOL scores, and
in nerve conduction studies (NCS) including nerve conduction
velocity (NCV) and compoundmotor action potentials (CMAPs)
that persisted for the 5 years of follow-up observation (16). Costs
and re-imbursement for HSCT were not captured during that
study.We, therefore, undertook an analysis of cost for autologous
HSCT between 2017 and 2019 compared to published literature
for those on IVIG treatments.
METHODS
Setting and Design
Enrollment in the CIDP HSCT trial was completed in 2016
and published in June 2020 (16). As the costs of HSCT in
that study could not be retrospectively recovered, we analyzed
the costs of HSCT between January 2017 and January 2019 for
patients treated in an identical manner using the same protocol
and same eligibility and standard of care guidelines. Costs were
compared to recent published literature on costs for treating
CIDP with IVIG.
Eligibility
As described previously (16), eligible patients had definitive
CIDP according to the European Federation Neurologic
Societies/Peripheral Nerve Society (EFNS/PNS) criteria (1) and
dependence on or failure of at least two of the following three
standard treatments: corticosteroids, IVIG, or PLEX (16).
Autologous Hematopoietic Stem Cell
Transplantation
As previously described (16), peripheral blood hematopoietic
stem cells were collected using cyclophosphamide (2 g/m2)
and filgrastim (5–10 mcg/kg/day), cryopreserved, thawed, and
refused without manipulation after receiving a conditioning
regimen of cyclophosphamide (200mg/kg), rabbit antithymocyte
globulin (rATG) (5.5 mg/kg), and rituximab 1,000mg.
Supportive care guidelines were previously reported (16).
Hematopoietic Stem Cell Transplantation
Costs
Except for physician billing, all hospital transplant related
costs were counted including: blood draws, laboratory tests,
imaging studies, peripheral blood stem cell collection and
reinfusion, nursing care, packed red blood cell and platelet
transfusions, room charges, and oral or intravenous medications
including electrolyte infusions, diuretics, antibiotics, anti-
emetics, and fluids.
HSCT costs are reported as direct, overhead, and total costs.
Direct costs are costs of patient treatment and care. Overhead
costs are the management and maintenance expenses required
to run a hospital. The sum of direct and overhead costs are
total costs.
IVIG Costs
We searched PubMed for all manuscripts (excluding abstracts
and non-peer-reviewed materials) under the terms “CIDP,”
“costs,” and “immunoglobulin” published over roughly the same
time interval (years 2014–2020) as the data collected on costs for
patients undergoing hematopoietic stem cell transplantation, i.e.,
years 2017–2019.
Outcomes
In order to assess cost effectiveness, we searched PubMed
under the terms “CIDP,” “IVIG,” and “hematopoietic stem cell
transplantation” for clinical outcomes between treatment with
IVIG vs. HSCT. Search parameters were limited to English and
the decade of 2014–2020. The intent of this analysis is to provide
an initial platform to support a more in depth future analysis
of the healthcare economics of HSCT vs. IVIG for chronic
progressive CIDP. Clinical outcomes included were INCAT
disability score, MRC sum score, hand grip strength, QOL, or
NCS including NCV or CMAPs.
Statistics
Due to absence of prospective comparison data available in
the literature, costs are based on single treatment studies and
could not be based on randomized comparisons between IVIG
and HSCT. We calculated the mean HSCT cost in the entire
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FIGURE 1 | Cost of HSCT in US dollars per CIDP patient. CIDP, chronic inflammatory demyelinating polyradiculoneuropathy; HSCT, hematopoietic stem cell
transplantation; US, United States.
cohort and for each patient in order to represent deviation
of each patient from the mean. Similarly, outcome measures
could not be obtained from randomized trials, but are included
as a rough estimate to gauge cost effectiveness for patients
who are maintained on IVIG vs. those who undergo a one-




We found no previously published manuscripts on the cost
of autologous HSCT for CIDP. The mean direct, overhead,
and total costs of HSCT were $62,131 (range $32,942–168,097),
$46,446 (range $21,386–62,555), and $108,577 (range $56,327–
277,119), respectively (Figure 1). The mean revenue collected
and net profit was $140,812 (range $72,702–278,722) and $31,531
(range $68,673 to –30,740) per patient, respectively. As shown
in Figure 1, there was one outlier with high HSCT costs of
$277,119 that drove the mean total costs from $99,218 (mean for
18 patients) to $108,576 (mean for 19 patients), and a second low
outlier in net profit, i.e., a loss of $30,740, due to fixed below cost
medicare reimbursement rules.
The outlier with high cost was a patient receiving daily IVIG
5 times a week alternating with 4 times a week every other
week. While in all other patients, IVIG was discontinued on
day of hospital admission, this patient had a history of sudden
neurologic deterioration requiring intensive care unit admission
when a single dose of IVIG was delayed. For that reason, the
patient was maintained on IVIG during HSCT and those costs
were included in his HSCT billing. The patient was losing
intravenous access from chronic IVIG administration and had
a broken and retained intravascular central line whose removal
further inflated costs.
Cost of IVIG for CIDP
Review of the literature, excluding abstracts, meeting
presentations, non-peer reviewed and Guillain-Barré syndrome
related papers, revealed five peer reviewed publications from the
USA (n = 2) (17, 18), UK (n = 1) (12), France (n = 1) (19),
and Germany (n = 1) (20) related to health care costs of CIDP
between 2014 and 2020 (Table 1). The costs of CIDP treatment
with IVIG was £49,430 in the UK (19) and e45,332 in Germany
(20) (Table 1). The French study reported that the cost for at
home infusion of IVIG was e48,189/year vs. e91,798/year for in
hospital infusions (19). In 2014, the annual cost for IVIG in the
USA was on average $108,016 per patient or $9,720 per infusion
(17). In 2018, the costs of treating CIDP in the USA was $136,892
(18). In all CIDP studies the main patient care cost, 51–67%, was
due to IVIG (Table 1).
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TABLE 1 | Examples of variability in cost of care for IVIG treatments vs. HSCT for CIDP from one center.
Study/Country/Year
(reference)
Cost per patient Comment
IVIG treatments
Mengel/Germany/2018 (20) e45,332 per year 67% of cost relates to cost of IVIG given in hospital
Madhi-Rogers/UK/2014 (12) £49,430 per year 62% of cost relates to cost of IVIG given in hospital
Le Masson/France/2017 (19) e48,189 per year at home
e91,798 per year
in hospital enditemize
Cost of IVIG given at home vs. in hospital
Guptill/USA/2014 (17) $108,016 per year ($9,720 per infusion)
Divino/USA/2018 (18) $136,892 per year 51.2% of cost relates to cost of IVIG given in
hospital
HSCT
Burt/USA/2020 $108,577 (one time cost not
per year)
Revenue collected $140,812
e, euro; £, pound; $, dollar; CIDP, chronic inflammatory demyelinating polyradiculoneuropathy; IVIG, intravenous immunoglobulin; UK, United Kingdom; USA, United States of America.
TABLE 2 | Comparison of changes in outcome parameters from baseline for ICE (IVIG) and PATH (SCIg) studies vs. hematopoietic stem cell transplantation (HSCT).
Study (number of patients) INCAT disability
score
MRC sum score Dominant Grip
Kg
NCV (m/Sec) CMAP (millivolts) SF-36 QOL
physical/mental
IVIG studies for naïve or minimally IVIG treated (<4 infusion in 9 months) CIDP
ICE Study baseline (N = 59) (reference 4) 4.2 49.3 48.2 NR NR 31.1/46.3
ICE 1st 24 weeks of IVIG change from
baseline
−1.1 +3.3 +13.2 NR NS +5.7/+3.3
ICE 2nd 24 weeks of IVIG change from
baseline
0.1 0.8 −0.8 NR NR NR
PATH Study low dose baseline (N = 57)
(reference 5)
2.0 75 67 NR NR NR
PATH low-dose SCIg 24 week change
from baseline
0 0 −0.6 NR NR NR
PATH study high dose baseline (N = 58)
(reference 5)
2.0 76 68.4 NR NR NR
PATH High-dose SCIg 24 week change
from baseline
0 0 −2.7 NR NR NR
HSCT for chronic IVIG dependent CIDP (n = 60) (reference 16)
Baseline value 4.4 51.8 18 22.7 3.55 29.3/47.7
6 month −1.3 +3.0 +4.7 +8.8 +0.14 +19.5/+16.7
1 year −2.3 +5.2 +8.3 +10.8 +1.08 +28.3/+19.7
2 years −2.3 +5.2 +11.2 +11.1 +1.03 +27.9/+21
3 years −2.3 +5.2 +10.8 +15 +1.69 +33.4/+25.4
4 years −2.4 +5.2 +12.4 +15.4 +1.72 +30.3/+22.8
5 years −2.6 +5.2 +12.8 +15.6 +0.57 +36.6/+33
CMAP, compound motor action potential; ICE, Intravenous immune globulin for chronic inflammatory demyelinating polyradiculoneuropathy; HSCT, hematopoietic stem cell
transplantation; INCAT, inflammatory neuropathy cause and treatment; IVIG, intravenous immunoglobulin; MRC, medical research council; NCV, nerve conduction velocity; NR, not
reported; NS, not significant; QOL, quality of life; PATH, Polyneuropathy And Treatment with Hizentra; SCIg, subcutaneous immunoglobulin; SF-36, short form 36. From ICE study (4)
and PATH study (5).
Clinical Outcome: IVIG vs. HSCT
INCAT disability scale gives 5 points for upper and 5 for lower
limb dysfunction with a total score of 10 that goes from 0
for normal to 10 for incapacitated upper and lower limbs.
The ground-breaking ICE study of IVIG enrolled 59 treatment
naïve CIDP patients with significant disability (mean INCAT
score of 4.2) and demonstrated significant improvements after
24 weeks (4). During the second 24-week extension phase,
patients remained stable (Table 2). The SCIg PATH study
enrolled 59 treatment naïve of minimally treatment experienced
(∼1/3 of the study cohort received on average 4 courses
IVIG over 9 months) patients with less severe disease (mean
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FIGURE 2 | Quality of life as measured by the SF-36 rating scale at baseline and for up to 5 years after hematopoietic stem cell transplantation (HCST).
INCAT score of 2.0) (5). The PATH study demonstrated a
significant treatment effect compared to continued decline on
placebo, both with low (0.2 g/kg) or high (0.4 g/kg) SCIg
dosing. However, when compared to base line, the mean
INCAT scores did not improve (Table 2). For treatment of
a chronic disease, both of these pivotal studies had relatively
short follow-up of 48 and 24 weeks, respectively. Neither study
reported full results of NCS although ICE reported no significant
changes in CMAP compared to placebo. ICE reported no
significant improvement in quality of life compared to placebo
control (21).
In the only prospective autologous HSCT trial for CIDP, 60
patients were selected for being IVIG dependent with a mean
treatment duration of 6 years and a significant chronic baseline
disability (mean INCAT score of 4.4) (16). Following a one-
time treatment with autologous HSCT, patients had significant
improvements in INCAT score, QOL, and both NCV and
CMAP that persisted for 5 years (Table 2, Figure 2). During a
5-year interval after HSCT, all patients demonstrated marked
improvements in unassisted ambulation and 80% of patients
remained free of all immune-based therapies including IVIG
(Figure 3) (16).
DISCUSSION
By convention, whenever, hematopoietic stem cells are infused
after chemotherapy, the procedure is called a hematopoietic
stem cell transplant. In reality, there is no transplant of
foreign tissue or transplant of autologous tissue to a
heterologous location. The unmanipulated hematopoietic
stem cells have no disease-specific or disease-modulating
effects. In fact, since the conditioning regimen herein is non-
myeloablative, hematopoietic recovery will occur without
infusion of previously collected autologous hematopoietic
stem cells. Thus, the hematopoietic stem cells are in reality
an autologous supportive blood product transfused to
shorten the period of chemotherapy-induced cytopenias,
i.e., anemia, thrombocytopenia, and neutropenia, similar
to the rationale for infusion of platelets or red blood cells
after chemotherapy.
HSCT, unlike immune suppressive pharmacology drugs, is
given as a once-only treatment. The mechanism of autologous
HSCT is based on the rationale that removal of lymphocytes
with a short course of chemotherapy/biologics (6 days) and
subsequent regeneration of hematopoiesis over 9–10 days
occurring in the absence of cytokine inflammatory signals will
result in a return of tolerance toward self-epitopes and self-
tissue. In order to confirm this hypothesis, immune analysis
before and after HSCT for autoimmune disorders is an area
of active research. Autologous non-myeloablative HSCT for
multiple sclerosis, an immune-mediated central nervous system
demyelinating disease, resulted in an increased diversity and
normalization of the T cell receptor repertoire consistent with
“out with the old and in with the new” (22, 23). After HSCT, there
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FIGURE 3 | (A) Demonstrates freedom from immunological therapies for up to 5 years after hematopoietic stem cell transplantation (HSCT). (B) Demonstrates
reduction in use of ambulatory aids for up to 5 years after HSCT. Replicated with permission from source (16).
is also an increase in recent thymic emigrants and suppressor T
regulatory cells (Treg) (24–26) consistent with re-establishment
of tolerance.
The mean per CIDP patient annual IVIG treatment costs
in the USA were reported to be $108,016 and $136,892 in
2014 and 2018, respectively (17, 18) which is approximately
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equal to the cost of HSCT (cost $108,577, revenue collected
$140,812). Since HSCT is a one-time treatment and 80% of
patient remain treatment-free for over 5 years after HSCT (16),
the projected health care savings per patient over that 5-
year interval would be $438,054 ($136,892 × 4 × 0.8).
However, this estimate may be an under-estimate since it
assumes that IVIG prices will not increase over that 5-year
interval and is based on health care costs for the average
CIDP patient.
The patients treated with HSCT were not representative
of the overall CIDP population as they did not remit with
chronic IVIG therapy (average 6 years) and the dosages of
IVIG were higher than the average patient. The immediate pre-
HSCT mean monthly dose of IVIG was 151 grams in this
cohort of patients. For a seventy-kilogram person infused at
500 mg/kg, each infusion would be 35 grams. Thus, to reach a
mean IVIG dose 151 grams per month, each person on average
would receive 4.3 infusions a month. Since the average cost per
IVIG infusion in the USA has been reported to be $9,720, and
patients on average received 4.3 infusions per month, the IVIG
costs would be $41,796 per month. In this subset of patients,
the revenue collected from HSCT ($140,812) would therefore
pay for itself after stopping 4 months of conventional IVIG
treatment ($140,812/41,796).
There are several limitations of this study. The cost for HSCT
is from one center while costs for HSCT would likely be affected
by agents used in the conditioning regimen, whether the regimen
is myeloablative or non-myeloabaltive, center experience, and
national and international regional variation. For example, in
the United Kingdom (UK) National Health Service (NHS) the
cost of HSCT is approximately £30,000–35,000 compared to
an annual UK cost for IVIG of £49,430 (12, 13). While costs
for HSCT in the UK public health system appears cheaper, in
public health systems, the overhead costs are not included in
patient costs. In contrast, in the American private health care
system both direct costs and overhead costs are included because
both must be recovered in the patient billing. Furthermore,
while patients stopped and remained off IVIG and other
immune based treatments after HSCT, other post-transplant
costs, e.g., blood monitoring, are not included. Outpatient
pharmaceutical IVIG rebates are proprietary information that
could not be factored into this analysis. A long-term parameter
affecting cost effectiveness is risk of late malignancies. None
of the patients undergoing HSCT with the less intense non-
myeloablative regimen developed a malignancy. However, the
risk of malignancy will depend on the conditioning regimen,
will take long-term (>10–20 years) follow-up, and will likely
vary between regimens with the more intense myeloablative
regimens containing multiple high dose alkylating agents and or
irradiation having a higher risk. Finally, this analysis does not
factor in loss of work productivity and wages from CIDP related
disability which due to the superior health outcome and reversal
of neurologic disability after HSCT should favor HSCT compared
to continuing IVIG.
Finally, immunoglobulin availability and costs vary widely
depending on the product (https://bnf.nice.org.uk/medicinal-
forms/normal-immunoglobulin.html), with manufacturers
ranging from pharmaceutical companies to transfusion
services. Moreover, irrespective of cost, there are important
considerations relating to availability of a non-renewable limited
supply of immunoglobulins as a pooled human blood product.
In view of this, some health services, such as the UK NHS,
enforce demand management schemes whereby administration
and expenditure can be monitored and regulated (http://igd.
mdsas.com/).
As costs will differ between health services, manufacturers of
immunoglobulins (pharmaceutical or transfusion services) and
providers of HSCT, further studies are required to determine
cost-effectiveness of HSCT across local settings. Independent of
costs, there are also important considerations related to supply
of immunoglobulins that are derived from a finite quantity of
pooled human blood products.
SUMMARY
This is the first report of comparison of costs and health
outcomes for HSCT compared to chronic IVIG that, over a
5-year interval and in properly selected patients, appears to
result in a health care savings of ∼500,000.00 US dollars per
patient. It appears that when using a non-myeloablative regimen
in properly selected patients that HSCT may be performed
safely, could achieve a substantial cost savings for private or
public insurance, and give superior results such as improvement
in NCS and QOL compared to continued IVIG. However,
further investigation and analysis are needed and appear to
be warranted.
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